Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study

Table 5 Changes of eGFR (ml/min/1.73m²) over time assessed by linear mixed effects models for patients treated with TDF vs. untreated

	Crude model		Adjusted for baseline age, gender, ethnicity
	Coefficient β (95% CI)	p-value	Coefficient β (95% CI)	p-value
(Intercept)	85.813 (84.676, 86.950)	< 0.001	93.974 (90.352, 97.595)	< 0.001
Group	0.991 (− 1.085, 3.068)	0.349	1.76 (− 0.286, 3.805)	0.092
Time	− 0.014 (− 0.050, 0.022)	0.449	−0.016 (− 0.051, 0.019)	0.379
Group x Time ^a	−0.034 (− 0.094, 0.027)	0.278	−0.033 (− 0.092, 0.026)	0.268

^a x indicates the interaction between group and follow-up time. Group = {0,1}, where 0 indicates untreated, 1 indicates TDF. CI confidence interval; eGFR estimated glomerular filtration rate; TDF Tenofovir disoproxil fumarate

ISSN: 1471-2334